Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Gluclazide SR - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Gluclazide SR

Approved

STANDARD

Gluclazide SR

Krka, D.D., Novo Mesto🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 4373c72cb457c28e
Company: Krka, D.D., Novo Mesto
Type: Standard

Approval Details

Approval Id: 4373c72cb457c28e
Drug Approval Philippines Name: Gluclazide SR
Product Name: Gluclazide SR
Registration Number: DRP-16291
Brand Name: Gluclazide SR
Generic Name: Gliclazide
Dosage Form: Prolonged-Release Tablet
Dosage Strength: 30 mg
Manufacturer: Krka, D.D., Novo Mesto
Importer: Ambicare Pharmaceuticals Inc.
Distributor: Ambicare Pharmaceuticals Inc.
Company Detail Path: /organization/krka-d-d-novo-mesto
Issuance Date: 28 January 2025
Expiry Date: 28 January 2030
Pharmacologic Category: Blood Glucose Lowering Drug
Classification: Prescription (Rx) Drug

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

4373c72cb457c28e

Type

Standard

Back to Philippines FDA Approvals